The firm recently won an NIH grant to develop its instrument-free gonorrhea test, and is also developing a chlamydia assay with the long-term goal of making a combined CT/NG test.
The test runs on the firm's high throughput platforms and has claims for extragenital samples in addition to traditional samples.
Solid MDx revenue growth was driven primarily by sales of Aptima women's health products on the Panther and Tigris platforms.
A koala genome bank aims to increase healthy genes in its population and reduce chlamydia infections, according to Australian Geographic.
The test detects chlamydia, gonorrhea, and trichomonas from a single patient sample.
Revenues from the company’s molecular diagnostics business grew 6 percent, driven by continued strength in sales of women's health products.
The automated device was able to detect pathogens from clinical samples and can be built from a 3D printer retailing at $750 or less.
Sequences from Chlamydia trachomatis strains in northern Australia suggest trachoma infections in the eye may be caused by small changes to urogenital strains.
The firm has improved design of the system for low-resource settings and validated it on clinical chlamydia samples and extracted HIV, Ebola, and dengue samples.
The revenue increase was driven by growth in Meridian's Diagnostics segment and particularly sales of its Illumigene product line.
In Science this week: genetic target for urothelial bladder cancer treatment, and more.
At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.
Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.
Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.